Cargando…
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
BACKGROUND: Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer with symptomatic bone metastases. The bone scan response to radium-223 has only been described in one single center trial of 14 patients, none of whom achieved the outstandin...
Autores principales: | McNamara, Megan A, George, Daniel J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426169/ https://www.ncbi.nlm.nih.gov/pubmed/25948240 http://dx.doi.org/10.1186/s12885-015-1390-y |
Ejemplares similares
-
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
por: Sidhu, Amanjot, et al.
Publicado: (2023) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015) -
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018) -
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)